Imetelstat Presentations and Publications

Presentations

Publications

  • Roeth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L) – Telomerase-based cancer therapy. Recent Results in Cancer Research 2010; 184:221-34.
    Read publication
  • Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, Mickey BE, Wright WE, Shay JW, Bachoo RM. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res. 2010 Jan 1;16(1):154-63.
    Read publication
  • Sarah K. Brennan, Qiuju Wang, Robert Tressler, Calvin Harley, Ning Go, Ekaterina Bassett, Carol Ann Huff, Richard J. Jones, William Matsui. Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms. PLoS One. 2010 Sep 1;5(9).
    Read publication
  • Immanual Joseph, Robert Tressler, Ekaterina Bassett, Calvin Harley, Christen M. Buseman, Preeti Pattamatta, Woodring E. Wright, Jerry W. Shay, and Ning F. Go. The Telomerase Inhibitor Imetelstat Depletes Cancer Stem Cells in Breast and Pancreatic Cancer Cell Lines. Cancer Res. 2010 Nov 15;70(22):9494-504.
    Read publication
  • Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, Shen C, Herbert BS. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther. 2009 Jul;8(7):2027-35.
    Read publication
  • Harley CB. Telomerase and cancer therapeutics. Nature Reviews Cancer 2008; 8:167-179.
    Read publication
  • Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res. 2006 May 15;12(10):3184-92.
    Read publication
Close
Form content here please :)